A new market beckons for Alzheimer’s blood tests
If drugs acting on amyloid and tau can defy the sector’s history of failure, the testing landscape will change dramatically.
Diasorin heads to the US with $1.8bn Luminex deal
And consolidation in the diagnostics space is only just beginning.
Invitae borrows against the future
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.
